Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 216 of 6351
-
New oral drug aims to slow Alzheimer's in its earliest stages
Disease control Recruiting nowA randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease. Ba…
Phase 2 • Sponsor: NeuroBiogen Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Triple-Drug attack on brain metastases: new hope for melanoma patients?
Disease control Recruiting nowThis is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill may help teens regrow hair lost to alopecia
Disease control Recruiting nowThis study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Phase 3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Virus cocktail aims to make inoperable esophageal cancer removable
Disease control Recruiting nowThis clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). The primary end…
Phase 1/2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can a second intervention save the brain after a mild stroke?
Disease control Recruiting nowA prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic s…
Sponsor: First Affiliated Hospital of Wannan Medical College • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a diabetes drug clear fluid from lungs in heart failure?
Disease control CompletedThis randomized controlled trial evaluates the efficacy and tolerability of early initiation of dapagliflozin in adult patients hospitalized with acute heart failure (AHF). The study aims to assess the effect of dapagliflozin on pulmonary congestion as measured by lung ultrasound…
Phase 4 • Sponsor: May Mohamed Abdalla • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can wearables and blood tests predict brain injury from blasts?
Knowledge-focused CompletedRepetitive blast exposure has been shown to lead to more severe neurobehavioral impairments versus a single exposure. Blast-induced Traumatic Brain Injury (TBI) can lead to short- and long-term adverse outcomes Even mild brain injuries can impair neurocognitive performance, and r…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Cholesterol-Lowering drug may boost lung cancer immunotherapy
Disease control Recruiting nowThis is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Phase 3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gut bacteria may fortify bones in breast cancer therapy
Disease control Recruiting nowThis phase II trial tests how well a probiotic, WBF-038, works in preventing bone loss in patients with early-stage hormone receptor-positive breast cancer who are starting treatment with aromatase inhibitors. Aromatase inhibitors are a drug that blocks the activity of an enzyme …
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a nerve graft in the brain boost the effects of deep brain stimulation for Parkinson's?
Disease control Recruiting nowThe investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nig…
Phase 1 • Sponsor: Craig van Horne, MD, PhD • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
Disease control Recruiting nowThis phase II trial studies how well personalized neck radiation therapy directed by sentinel lymph node biopsy (SLNB) works in treating patients with oral cavity squamous cell carcinoma (OCSCC). SLNB can be performed as part of standard care for OCSCC. During SLNB, a radiotracer…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy builds Cancer-Killing cells inside you – no lab needed
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Phase 1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a personalized vaccine plus targeted drug outsmart recurrent brain tumors?
Disease control Recruiting nowThe purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Phase 1 • Sponsor: Katy Peters, MD, PhD • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New shorter chemo combo shows promise for hodgkin lymphoma
Disease control Recruiting nowThe purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective t…
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
Disease control Recruiting nowThe purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severel…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug cocktail aims to tackle recurrent head and neck cancer
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-…
Phase 1/2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Radiation-Immuno combo targets tough liver cancer clot
Disease control Recruiting nowPatients with PVTT involvement is a significant healthcare burden as they are present in up to 40% of patients with HCC at diagnosis. These patients exhibit a poorer prognosis compared to patients without PVTT, as a result they were often excluded from existing pivotal clinical t…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for tough lung cancers: ivonescimab combo enters phase 3 trial
Disease control Recruiting nowThis is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based t…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC